Otsuka Pharmaceuticals
The new smartphone app, Rejoyn, will deliver treatment to patients taking antidepressant medication aimed at enhancing cognitive control of emotion.
Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.
The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.
The industry is better off viewing the the floundering deals between Onduo and Sanofi, Proteus and Otsuka, and Pear and Sandoz as a learning opportunity.
The digital pill maker's employees were brought back after the company secured $5 million in emergency funding, but CNBC's report suggests that several are now looking elsewhere for work.
Otsuka intends to invest more than $300 million in an FDA-cleared software app that will apply cognitive therapy principals either with or without prescription drugs.
As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies.